# Effects of Itraconazole and Rifampin on the Blood Tazemetostat Levels

> **NCT04537715** · PHASE1 · COMPLETED · sponsor: **Epizyme, Inc.** · enrollment: 42 (actual)

## Conditions studied

- All Malignancies
- Advanced Malignancies
- Hematologic Malignancy
- Solid Tumor
- Follicular Lymphoma (FL)
- Non-Hodgkin Lymphoma (NHL)
- Diffuse Large B-Cell Lymphoma (DLBCL)
- Epithelioid Sarcoma (ES)
- Synovial Sarcoma
- Renal Medullary Carcinoma
- Mesothelioma
- Rhabdoid Tumor

## Interventions

- **DRUG:** Tazemetostat
- **DRUG:** Itraconazole
- **DRUG:** Tazemetostat
- **DRUG:** Rifampin

## Key facts

- **NCT ID:** NCT04537715
- **Lead sponsor:** Epizyme, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-04-23
- **Primary completion:** 2023-04-03
- **Final completion:** 2023-04-03
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2025-02-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04537715

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04537715, "Effects of Itraconazole and Rifampin on the Blood Tazemetostat Levels". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04537715. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*